149 related articles for article (PubMed ID: 32179445)
1. Diagnosing deficits in quality of life and providing tailored therapeutic options: Results of a randomised trial in 220 patients with colorectal cancer.
Klinkhammer-Schalke M; Steinger B; Koller M; Zeman F; Fürst A; Gumpp J; Obermaier R; Piso P; Lindberg-Scharf P;
Eur J Cancer; 2020 May; 130():102-113. PubMed ID: 32179445
[TBL] [Abstract][Full Text] [Related]
2. Direct improvement of quality of life in colorectal cancer patients using a tailored pathway with quality of life diagnosis and therapy (DIQOL): study protocol for a randomised controlled trial.
Klinkhammer-Schalke M; Lindberg P; Koller M; Wyatt JC; Hofstädter F; Lorenz W; Steinger B
Trials; 2015 Oct; 16():460. PubMed ID: 26467994
[TBL] [Abstract][Full Text] [Related]
3. Direct improvement of quality of life using a tailored quality of life diagnosis and therapy pathway: randomised trial in 200 women with breast cancer.
Klinkhammer-Schalke M; Koller M; Steinger B; Ehret C; Ernst B; Wyatt JC; Hofstädter F; Lorenz W;
Br J Cancer; 2012 Feb; 106(5):826-38. PubMed ID: 22315052
[TBL] [Abstract][Full Text] [Related]
4. Quality of life after total laparoscopic hysterectomy versus total abdominal hysterectomy for stage I endometrial cancer (LACE): a randomised trial.
Janda M; Gebski V; Brand A; Hogg R; Jobling TW; Land R; Manolitsas T; McCartney A; Nascimento M; Neesham D; Nicklin JL; Oehler MK; Otton G; Perrin L; Salfinger S; Hammond I; Leung Y; Walsh T; Sykes P; Ngan H; Garrett A; Laney M; Ng TY; Tam K; Chan K; Wrede CD; Pather S; Simcock B; Farrell R; Obermair A
Lancet Oncol; 2010 Aug; 11(8):772-80. PubMed ID: 20638899
[TBL] [Abstract][Full Text] [Related]
5. Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non-small-cell lung cancer (KEYNOTE-189): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.
Garassino MC; Gadgeel S; Esteban E; Felip E; Speranza G; Domine M; Hochmair MJ; Powell S; Cheng SY; Bischoff HG; Peled N; Reck M; Hui R; Garon EB; Boyer M; Wei Z; Burke T; Pietanza MC; Rodríguez-Abreu D
Lancet Oncol; 2020 Mar; 21(3):387-397. PubMed ID: 32035514
[TBL] [Abstract][Full Text] [Related]
6. Effect of general practitioner-led versus surgeon-led colon cancer survivorship care, with or without eHealth support, on quality of life (I CARE): an interim analysis of 1-year results of a randomised, controlled trial.
Vos JAM; Duineveld LAM; Wieldraaijer T; Wind J; Busschers WB; Sert E; Tanis PJ; Verdonck-de Leeuw IM; van Weert HCPM; van Asselt KM;
Lancet Oncol; 2021 Aug; 22(8):1175-1187. PubMed ID: 34224671
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the FACT-C, EORTC QLQ-CR38, and QLQ-CR29 quality of life questionnaires for patients with colorectal cancer: a literature review.
Ganesh V; Agarwal A; Popovic M; Cella D; McDonald R; Vuong S; Lam H; Rowbottom L; Chan S; Barakat T; DeAngelis C; Borean M; Chow E; Bottomley A
Support Care Cancer; 2016 Aug; 24(8):3661-8. PubMed ID: 27193118
[TBL] [Abstract][Full Text] [Related]
8. A Randomized Controlled Trial of a Nurse-Led Supportive Care Package (SurvivorCare) for Survivors of Colorectal Cancer.
Jefford M; Gough K; Drosdowsky A; Russell L; Aranda S; Butow P; Phipps-Nelson J; Young J; Krishnasamy M; Ugalde A; King D; Strickland A; Franco M; Blum R; Johnson C; Ganju V; Shapiro J; Chong G; Charlton J; Haydon A; Schofield P
Oncologist; 2016 Aug; 21(8):1014-23. PubMed ID: 27306909
[TBL] [Abstract][Full Text] [Related]
9. Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial.
Brahmer JR; Rodríguez-Abreu D; Robinson AG; Hui R; Csőszi T; Fülöp A; Gottfried M; Peled N; Tafreshi A; Cuffe S; O'Brien M; Rao S; Hotta K; Zhang J; Lubiniecki GM; Deitz AC; Rangwala R; Reck M
Lancet Oncol; 2017 Dec; 18(12):1600-1609. PubMed ID: 29129441
[TBL] [Abstract][Full Text] [Related]
10. Quality of life after postmastectomy radiotherapy in patients with intermediate-risk breast cancer (SUPREMO): 2-year follow-up results of a randomised controlled trial.
Velikova G; Williams LJ; Willis S; Dixon JM; Loncaster J; Hatton M; Clarke J; Kunkler IH; Russell NS;
Lancet Oncol; 2018 Nov; 19(11):1516-1529. PubMed ID: 30337220
[TBL] [Abstract][Full Text] [Related]
11. Quality-of-Life Analysis of the German Prospective Multicentre Trial of Single-cycle Adjuvant BEP Versus Retroperitoneal Lymph Node Dissection in Clinical Stage I Nonseminomatous Germ Cell Tumours.
Flechtner HH; Fischer F; Albers P; Hartmann M; Siener R;
Eur Urol; 2016 Mar; 69(3):518-25. PubMed ID: 26620368
[TBL] [Abstract][Full Text] [Related]
12. Short-term results of quality of life for curatively treated colorectal cancer patients in Lithuania.
Lizdenis P; Birutis J; Čelkienė I; Samalavičius N; Kuliavas J; Slunskis V; Poškus T; Jotautas V; Poškus E; Strupas K; Saladžinskas Ž; Tamelis A
Medicina (Kaunas); 2015; 51(1):32-7. PubMed ID: 25744773
[TBL] [Abstract][Full Text] [Related]
13. Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial.
Harrington KJ; Ferris RL; Blumenschein G; Colevas AD; Fayette J; Licitra L; Kasper S; Even C; Vokes EE; Worden F; Saba NF; Kiyota N; Haddad R; Tahara M; Grünwald V; Shaw JW; Monga M; Lynch M; Taylor F; DeRosa M; Morrissey L; Cocks K; Gillison ML; Guigay J
Lancet Oncol; 2017 Aug; 18(8):1104-1115. PubMed ID: 28651929
[TBL] [Abstract][Full Text] [Related]
14. [Trans-sectoral care for patients with colorectal cancer: Design of a prospective randomized controlled multi-center trial (FKZ 01GY1143)].
Landenberger M; Boese S; Fach EM; Bauer A
Z Evid Fortbild Qual Gesundhwes; 2015; 109(2):171-80. PubMed ID: 26028456
[TBL] [Abstract][Full Text] [Related]
15. Quality of life in patients with recurrent ovarian cancer treated with niraparib versus placebo (ENGOT-OV16/NOVA): results from a double-blind, phase 3, randomised controlled trial.
Oza AM; Matulonis UA; Malander S; Hudgens S; Sehouli J; Del Campo JM; Berton-Rigaud D; Banerjee S; Scambia G; Berek JS; Lund B; Tinker AV; Hilpert F; Vázquez IP; D'Hondt V; Benigno B; Provencher D; Buscema J; Agarwal S; Mirza MR
Lancet Oncol; 2018 Aug; 19(8):1117-1125. PubMed ID: 30026000
[TBL] [Abstract][Full Text] [Related]
16. Cultural adaptation and validation of the Korean version of the EORTC QLQ-CR29 in patients with colorectal cancer.
Ihn MH; Lee SM; Son IT; Park JT; Oh HK; Kim DW; Kang SB
Support Care Cancer; 2015 Dec; 23(12):3493-501. PubMed ID: 25824366
[TBL] [Abstract][Full Text] [Related]
17. Postoperative pain and quality of life after lobectomy via video-assisted thoracoscopic surgery or anterolateral thoracotomy for early stage lung cancer: a randomised controlled trial.
Bendixen M; Jørgensen OD; Kronborg C; Andersen C; Licht PB
Lancet Oncol; 2016 Jun; 17(6):836-844. PubMed ID: 27160473
[TBL] [Abstract][Full Text] [Related]
18. Radiotherapy versus transoral robotic surgery and neck dissection for oropharyngeal squamous cell carcinoma (ORATOR): an open-label, phase 2, randomised trial.
Nichols AC; Theurer J; Prisman E; Read N; Berthelet E; Tran E; Fung K; de Almeida JR; Bayley A; Goldstein DP; Hier M; Sultanem K; Richardson K; Mlynarek A; Krishnan S; Le H; Yoo J; MacNeil SD; Winquist E; Hammond JA; Venkatesan V; Kuruvilla S; Warner A; Mitchell S; Chen J; Corsten M; Johnson-Obaseki S; Eapen L; Odell M; Parker C; Wehrli B; Kwan K; Palma DA
Lancet Oncol; 2019 Oct; 20(10):1349-1359. PubMed ID: 31416685
[TBL] [Abstract][Full Text] [Related]
19. Comparison of EORTC quality of life core questionnaire (EORTC-QLQ-C30) and gastrointestinal quality of life index (GIQLI) in patients undergoing elective colorectal cancer resection.
Schwenk W; Neudecker J; Haase O; Raue W; Strohm T; Müller JM
Int J Colorectal Dis; 2004 Nov; 19(6):554-60. PubMed ID: 15205989
[TBL] [Abstract][Full Text] [Related]
20. Health-related quality of life for immediate versus delayed androgen-deprivation therapy in patients with asymptomatic, non-curable prostate cancer (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial.
Duchesne GM; Woo HH; King M; Bowe SJ; Stockler MR; Ames A; D'Este C; Frydenberg M; Loblaw A; Malone S; Millar J; Tai KH; Turner S
Lancet Oncol; 2017 Sep; 18(9):1192-1201. PubMed ID: 28760403
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
